Cell Impact announces outcome in the exercise of warrants of series 2023/2024 TO2

Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) ("Cell Impact" or the "Company") today announces the outcome of exercise of warrants of series 2023/2024 TO2, which were issued in connection with the Company’s rights issue of units in December 2023. In total, 104,821,096 warrants of series 2023/2024 TO2 were exercised, corresponding to approximately 81 percent of the total number of outstanding warrants of series 2023/2024 TO2, for subscription of 104,821,096 shares at a subscription price corresponding to SEK 0.17 per share. Cell Impact will receive approximately SEK 18 million before issuing costs through the exercise of the warrants of series 2023/2024 TO2.

Background
The subscription period for exercise of warrants of series 2023/2024 TO2 took place during the period from and including 16 September 2024, up to and including 30 September 2024. The subscription price per share for exercising the warrants of series 2023/2024 TO2 was set to SEK 0.17, corresponding to 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the measurement period 2 September 2024 up to and including 13 September 2024.

In total, 104,821,096 warrants of series 2023/2024 TO2 were exercised for subscription of 104,821,096 shares, corresponding to approximately 81 percent of the total number of warrants of series 2023/2024 TO2.

Shares that have been subscribed and paid for will be registered on the subscriber’s securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Cell Impact.

Number of shares, share capital and dilution
Through the exercise of the warrants of series 2023/2024 TO2, the number of shares in Cell Impact increased by 104,821,096 shares, from 591,450,032 shares to a total of 696,271,128 shares. The share capital will increase by approximately SEK 12,133,686.80, from approximately SEK 68,463,980.24 to approximately SEK 80,597,667.04.

For existing shareholders who did not exercise any warrants of series 2023/2024 TO2, the dilution amounts to approximately 15 percent of the number of shares and votes in the Company.

Advisers
Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner and Pareto Securities AB as Joint Bookrunner. Advokatfirman Vinge is a legal adviser to the Company and Baker McKenzie represents Sole Global Coordinator and Joint Bookrunners in connection with the rights issue.

This information is inside information that Cell Impact AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on 1 October 2024 at 16:45 CEST.